Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on February 23, 2005, detailing two key events. Firstly, the company entered into Amendment No. 5 to its Manufacturing Agreement with Merck & Co., Inc. This amendment extends the agreement, under which Regeneron produces an intermediate for a Merck pediatric vaccine, through October 31, 2006, with an option for Merck to extend for another year. This extension provides continued revenue visibility from this partnership. Secondly, the filing includes a press release announcing Regeneron's financial and operating results for the quarter and year ended December 31, 2004. While the specifics of these results are not detailed within the 8-K text itself, their inclusion signifies a material update for investors regarding the company's performance and financial condition as of the end of 2004.
Key Highlights
- 1Regeneron and Merck & Co., Inc. amended their Manufacturing Agreement, extending production of a pediatric vaccine intermediate.
- 2The manufacturing agreement is extended through October 31, 2006, with an option for Merck to extend through October 31, 2007.
- 3The amendment became effective as of January 1, 2005.
- 4Regeneron produces the vaccine intermediate at its Rensselaer, New York facility.
- 5The 8-K includes a press release detailing Regeneron's financial and operating results for the year and quarter ended December 31, 2004.
- 6The press release is furnished as an exhibit and not considered 'filed' for most SEC purposes.